39results about How to "Stabilize blood sugar levels" patented technology

Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

A composition for the treatment, prevention or management of a condition in primates, especially humans comprising a phenolic antioxidant-chromium complex.

A system is disclosed for optimizing exercise training of a diabetic exerciser. Computer software accepts physical status data and, in preferred embodiments, information regarding available exercise equipment, and formulates therefrom an optimized diet and exercise program, which is downloaded to an MP3 player or similar portable electronic device. The portable device directs the exerciser during workouts, while communicating with a blood glucose monitor and preferably with a heart rate monitor so as to monitor the exerciser's blood glucose level and heart rate during exercise, and warn the exerciser if the blood glucose level exceeds specified bounds. The portable device records a log of physiological data, exercise performed, and food consumed, for later upload to the computer and possible transmission to a healthcare provider. Preferred embodiments include only software. Other embodiments include a portable device, blood glucose monitor, heart rate monitor, or communications enabler.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a_2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α_2B; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α_2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α_2B; or the compounds are not antagonists of the adrenergic receptor α_2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α_2B, α_1B or α_2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α_2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α_2B; or the compounds are not antagonists of the adrenergic receptor α_2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

An apparatus and computerized method of intravenously monitoring a patient's blood chemistry transmits real time measurements to an electronically controlled closed loop system that auto-regulates blood osmolality and glucose level with medications infused through a catheter designed for such purpose. The closed loop system utilizes a glucose algorithm and an osmolality algorithm implemented in hardware and software to control the flow of dextrose, insulin and hypertonic saline to a patient in an effort to achieve better patient outcomes in instances of trauma, surgery and medical illnesses.

Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

The invention relates to a probiotic active product and a preparation method thereof. The probiotic active product comprises the following components in part by weight: 30 to 50 parts of bifidobacterium, 25 to 35 parts of lactobacillus Bulgaria, 25 to 35 parts of streptococcus thermophilus and 8 to 25 parts of trehalose. The preparation method for the probiotic active product comprises the following steps: respectively inoculating the bifidobacterium, the lactobacillus Bulgaria and the streptococcus thermophilus in a culture medium, and fermenting to obtain thallus; and then preparing the obtained thallus into the freeze dry bacterial powder probiotic active product by adopting a vacuum refrigerating and drying mode. The method prevents the activity of probiotic from being affected by oxygen in the production process by using an anaerobic technique and takes trehalose as a protective agent, so that the product containing high-activity probiotic is produced and the high activity of lactobacilli in a preservation period is maintained; meanwhile, the production process is simple and easy, and the manufacturing cost is low.

An edible product for normalizing blood sugar levels is provided. The product includes a mulberry extract having a (w/w) flavonoids concentration of at least 10%, a 1-deoxynojirimycin (DNJ) concentration of about 2% and a GABA concentration of about 1% of the total amino acid content of said mulberry extract.

A blood glucose monitoring and controlling system includes a detecting device and a liquid supplying device. The detecting device includes a first microneedle patch, a liquid pumping actuator, a sensor and a monitoring and controlling chip. The liquid supplying device includes a second microneedle patch, a liquid supplying actuator, a liquid supplying chamber and a liquid supplying and controlling chip. The detecting device is used to measure the blood glucose level of the user, and the liquid supplying device is used to supply insulin liquid. While the detecting device measures that the blood glucose level of the user is abnormal, the liquid supplying device is actuated to inject the insulin liquid into the user's body, thereby stabilizing the user's blood glucose level constantly.

The present application discloses high-temperature-resistant Chinese wolfberry fruit jam. The high-temperature-resistant Chinese wolfberry fruit jam comprises the following raw material components inparts by weight: 80-100 parts of Chinese wolfberry fruit slurry, 10-30 parts of trehalose, 0.5-0.8 part of pectin, 0.5-0.8 part of sodium alginate, 0.8-1.5 parts of citric acid and 0.04-0.08 part of calcium chloride. The present application solves a technical problem that the Chinese wolfberry fruit jam is not resistant to high temperature in the related art.

The present invention discloses a preparation method of a starch-based accessory material stabilizing blood sugar and belongs to the field of food accessory material processing. Common corns, wheat and other starch are used as main raw materials, common mulberry leaves, rhizoma polygonati, and radix puerariae are used as accessory materials, and a cycle gelatinization and aging treatment method isused to form the starch-based food accessory material stabilizing blood sugar. The medicinally and edibly homogenous food and slowly digested starch are organically combined, and the gelatinization and aging treatment method enables the obtained starch-based food accessory material to maintain a stabilized blood sugar level. The selected medicinally and edibly homogenous accessory materials havea function of reducing blood sugar by own. The starch-based accessory material stabilizing blood sugar also improves a content of the slowly digested starch and a thermal stability, and overcomes defects that a traditional slowly digested starch product is low in the content of the slowly digested starch and poor in thermal stability.

The invention relates to a medical biocolloid solution and a preparation method thereof and belongs to the technical field of medicinal instruments. The medical biocolloid solution is prepared from the ingredients in percentage by weight: 0.1-3% of chitosan quaternary ammonium salt, 0.5-4.5% of fucoidin, 0.1-2% of sodium chloride and the balance of water for injection. The medical biocolloid solution has very excellent technical effects on aspects, such as flushing effect, bacteriostasis effect, adverse reaction, biocompatibility, moisture retention property, bleeding arresting property and repairing action, and problems of the existing flushing products during use are solved, so that the medical biocolloid solution has very high advancement.

The present invention provides non-invasive diagnostic methods and kits for determining and/or monitoring oral health and glycemic control in subjects with Type 1 diabetes.

The invention provides trehalose bread and a preparation method thereof. The trehalose bread is prepared from the following raw materials in parts by weight: 70-75 parts of high-gluten flour, 30-40 parts of corn flour, 30-35 parts of black rice flour, 60-65 parts of eggs, 8-12 parts of butter, 1-2 parts of yeast, 2-3 parts of citric acid, 10-25 parts of trehalose, 5-8 parts of crystallized fructose and 5-7 parts of corn maltodextrin. The trehalose bread has the advantages of high softness and delicate taste.

The invention provides a traditional Chinese medicine composition for curing diabetes. The composition is obviously superior to the extract of each single medical herb, is safe and has no obvious toxic and side effects. The composition is prepared by the following raw materials according to the parts by weight: 51-746 parts of astragalus root extract and 285-2700 parts of loquat leaf extract, wherein, the astragalus root extract is prepared via astragalus root through water extraction or alcohol extraction, the content of the polysaccharide (active component) is higher than 80 percent (weight percentage), the loquat leaf extract is prepared via loquat leaves through water extraction or alcohol extraction, and the active component thereof, i.e. the total triterpenic acid from the loquat leaves comprises the following components 20-40 parts of maloic acid, 2-6 parts of oleanolic acid, 20-40 parts of corosolic acid and 8-20 parts of cralaegolic acid, wherein, the content of the total triterpenic acid from the loquat leaves is higher than 85 percent (weight percentage).

The invention discloses a formula and a preparation method of a weaned piglet antibiotic-free creep feed, and belongs to the technical field of antibiotic-free creep feeds, the weaned piglet antibiotic-free creep feed comprises the following raw materials by weight: 120-150 parts of a protein raw material, 170-190 parts of an energy raw material, and 110-130 parts of a functional antibiotic-replacing feed additive. According to the formula and the preparation method of the antibiotic-free creep feed for the weaned piglets, preferably selecting high-quality protein raw materials is very important, low-energy and moderate-protein-level are used, fibers are increased to enhance or prolong the satiety of sows, hunger stress can be reduced, and the fibers are beneficial to stabilizing the blood glucose concentration and improving the immunity of the sows. Moreover, the composition also has a stabilizing effect on insulin secretion, the weight gain is increased, endotoxin of intestinal tracts is mainly adsorbed, and the endotoxin in the body is adsorbed by lactobacillus, antibacterial peptide and plant essential oil by adding lactose, so that the health level rate of the body is increased.

One or more predetermined combination of human use (e.g., including animals) probiotics and specific ranges of ratio of anti-obesity human use probiotics compositions and their preparation methods and uses are provided. Particularly, the Present Disclosure provides a specific composition of food-grade probiotics been shaped by germ-free or antibiotics-treated dual-specificity phosphatase 6 (Dusp6) deficient mammal, which is effective in altering a relative abundance of gut microbiota and also useful in reducing body weight, fat mass, and/or size of adipocytes and increasing oxygen consumption and/or energy expenditure and thus can be used to treat or prevent obesity, manage blood glucose level, or their associated metabolic disorders or conditions in a subject in need.